Sulforaphane suppresses oligomerization of TLR4 in a thiol-dependent manner

Journal of Immunology

Volumn 184, Issue 1, 2010, Pages 411-419

  Youn, Hyung Sun ^a   Kim, Yoon Sun ^b   Park, Zee Yong ^b   Kim, So Young ^b   Choi, Na Young ^b   Joung, Sun Myung ^b   Seo, Jung A ^c   Lim, Kyung Min ^c   Kwak, Mi Kyoung ^d   Hwang, Daniel H ^e,f   Lee, Joo Young ^b  

^a Soonchunhyang University   (South Korea)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c AmorePacific Corporation   (South Korea)

^d Yeungnam University   (South Korea)

^e AGRICULTURAL RESEARCH SERVICE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYSTEINE; DITHIOTHREITOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; SULFORAPHANE; THIOL; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; SULFORAFAN; THIOCYANIC ACID DERIVATIVE; THIOL DERIVATIVE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BINDING SITE; C57BL 6 MOUSE; CYTOKINE PRODUCTION; DOWN REGULATION; EDEMA; ENZYME ACTIVATION; ENZYME DEGRADATION; FEMALE; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; TANDEM MASS SPECTROMETRY; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; DRUG EFFECT; HUMAN; IMMUNOLOGY; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELL LINE; CHROMATOGRAPHY, LIQUID; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOPRECIPITATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NF-KAPPA B; SIGNAL TRANSDUCTION; SULFHYDRYL COMPOUNDS; TANDEM MASS SPECTROMETRY; THIOCYANATES; TOLL-LIKE RECEPTOR 4; TRANSFECTION;

EID: 73949086542     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803988     Document Type: Article

References (34)

1. Clarke, J. D., R. H. Dashwood, and E. Ho. 2008. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett. 269: 291-304.
2. Heiss, E., C. Herhaus, K. Klimo, H. Bartsch, and C. Gerhäuser. 2001. Nuclear factor κB is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 276: 32008-32015.
3. Wierinckx, A., J. Brevé, D. Mercier, M. Schultzberg, B. Drukarch, and A. M. Van Dam. 2005. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J. Neuroimmunol. 166: 132-143.
4. Killeen, M. E., J. A. Englert, D. B. Stolz, M. Song, Y. Han, R. L. Delude, J. A. Kellum, and M. P. Fink. 2006. The phase 2 enzyme inducers ethacrynic acid, DL-sulforaphane, and oltipraz inhibit lipopolysaccharide- induced highmobility group box 1 secretion by RAW 264.7 cells. J. Pharmacol. Exp. Ther. 316: 1070-1079.
5. Liu, Y. C., C. W. Hsieh, Y. C. Weng, S. H. Chuang, C. Y. Hsieh, and B. S. Wung. 2008. Sulforaphane inhibition of monocyte adhesion via the suppression of ICAM-1 and NF-κB is dependent upon glutathione depletion in endothelial cells. Vascul. Pharmacol. 48: 54-61.
6. Wu, L., M. H. Noyan Ashraf, M. Facci, R. Wang, P. G. Paterson, A. Ferrie, and B. H. Juurlink. 2004. Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc. Natl. Acad. Sci. USA 101: 7094-7099.
7. Meylan, E., K. Burns, K. Hofmann, V. Blancheteau, F. Martinon, M. Kelliher, and J. Tschopp. 2004. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-κB activation. Nat. Immunol. 5: 503-507.
8. Fitzgerald, K. A., S. M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D. T. Golenbock, A. J. Coyle, S. M. Liao, and T. Maniatis. 2003. IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4: 491-496.
9. Sato, S., M. Sugiyama, M. Yamamoto, Y. Watanabe, T. Kawai, K. Takeda, and S. Akira. 2003. Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-κB and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171: 4304-4310. (Pubitemid 37238709)
10. Häcker, H., V. Redecke, B. Blagoev, I. Kratchmarova, L. C. Hsu, G. G. Wang, M. P. Kamps, E. Raz, H. Wagner, G. Häcker, et al. 2006. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439: 204-207.
11. Oganesyan, G., S. K. Saha, B. Guo, J. Q. He, A. Shahangian, B. Zarnegar, A. Perry, and G. Cheng. 2006. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439: 208-211.
12. Lee, J. Y., and D. H. Hwang. 2006. The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. Mol. Cells 21: 174-185.
13. Kanzler, H., F. J. Barrat, E. M. Hessel, and R. L. Coffman. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13: 552-559.
14. O'Neill, L. A. 2003. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr. Opin. Pharmacol. 3: 396-403.
15. Saitoh, S., S. Akashi, T. Yamada, N. Tanimura, M. Kobayashi, K. Konno, F. Matsumoto, K. Fukase, S. Kusumoto, Y. Nagai, et al. 2004. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int. Immunol. 16: 961-969.
16. Itoh, K., T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, et al. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236: 313-322.
17. Kwak, M. K., N. Wakabayashi, J. L. Greenlaw, M. Yamamoto, and T. W. Kensler. 2003. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol. Cell. Biol. 23: 8786-8794.
18. Rhee, S. H., and D. Hwang. 2000. Murine Toll-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF κB and expression of the inducible cyclooxygenase. J. Biol. Chem. 275: 34035-34040.
19. Park, B. S., D. H. Song, H. M. Kim, B. S. Choi, H. Lee, and J. O. Lee. 2009. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458: 1191-1195.
20. Kim, H. M., B. S. Park, J. I. Kim, S. E. Kim, J. Lee, S. C. Oh, P. Enkhbayar, N. Matsushima, H. Lee, O. J. Yoo, and J. O. Lee. 2007. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917.
21. Medzhitov, R., P. Preston-Hurlburt, and C. A. Janeway Jr. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397.
22. Zhang, H., P. N. Tay, W. Cao, W. Li, and J. Lu. 2002. Integrin-nucleated Toll-like receptor (TLR) dimerization reveals subcellular targeting of TLRs and distinct mechanisms of TLR4 activation and signaling. FEBS Lett. 532: 171-176.
23. Hong, F., M. L. Freeman, and D. C. Liebler. 2005. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem. Res. Toxicol. 18: 1917-1926.
24. Xu, C., G. Shen, C. Chen, C. Gélinas, and A. N. Kong. 2005. Suppression of NFkappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene 24: 4486-4495.
25. Jin, M. S., S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S. G. Paik, H. Lee, and J. O. Lee. 2007. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130: 1071-1082.
26. Takeuchi, O., T. Kawai, P. F. Mühlradt, M. Morr, J. D. Radolf, A. Zychlinsky, K. Takeda, and S. Akira. 2001. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13: 933-940.
27. Takeuchi, O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, and S. Akira. 2002. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169: 10-14. (Pubitemid 34686113)
28. de Bouteiller, O., E. Merck, U. A. Hasan, S. Hubac, B. Benguigui, G. Trinchieri, E. E. Bates, and C. Caux. 2005. Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J. Biol. Chem. 280: 38133-38145.
29. Liu, L., I. Botos, Y. Wang, J. N. Leonard, J. Shiloach, D. M. Segal, and D. R. Davies. 2008. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science 320: 379-381.
30. Youn, H. S., J. K. Lee, Y. J. Choi, S. I. Saitoh, K. Miyake, D. H. Hwang, and J. Y. Lee. 2008. Cinnamaldehyde suppresses Toll-like receptor 4 activation mediated through the inhibition of receptor oligomerization. Biochem. Pharmacol. 75: 494-502.
31. Youn, H. S., J. Y. Lee, S. I. Saitoh, K. Miyake, and D. H. Hwang. 2006. Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. Biochem. Biophys. Res. Commun. 350: 866-871.
32. Du, X., A. Poltorak, M. Silva, and B. Beutler. 1999. Analysis of Tlr4-mediated LPS signal transduction in macrophages by mutational modification of the receptor. Blood Cells Mol. Dis. 25: 328-338.
33. Youn, H. S., S. I. Saitoh, K. Miyake, and D. H. Hwang. 2006. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem. Pharmacol. 72: 62-69.
34. Lin, W., R. T. Wu, T. Wu, T. O. Khor, H. Wang, and A. N. Kong. 2008. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2-dependent pathway. Biochem. Pharmacol. 76: 967-973.